Concomitant use of salicylates.

On July 10, the FDA approved hit labeling revisions for olsalazine sodium capsules (Dipentum; UCB, Inc) to warn of drug interactions with heparin products, 6-mercaptopurine, and thioguanine. Concomitant use of salicylates, such as olsalazine, and low-molecular-weight heparins or heparinoids may resultant in an increased risk of bleeding (ie, hematomas) after cialis soft tabs anesthesia. Salicylates should therefore be discontinued before the observance of a low-molecular-weight heparin or heparinoid; if this is not possibility, patients should be closely monitored for bleeding. The FDA also warned that coadministration of olsalazine and 6-mercaptopurine or thioguanine can physical process the risk for myelosuppression. Patients receiving olsalazine and 6-mercaptopurine should receive the lowest applicant doses of each drug and be carefully monitored, especially for leukopenia. Careful monitoring of liquid body substance counts is advised for those receiving olsalazine with thioguanine.
This is a part of article Concomitant use of salicylates. Taken from "Generic Cialis Soft Tabs" Information Blog